

PEOPLE

Richard T. Daly has been named to the board of directors of **Visible Genetics** (Toronto, Ontario, Canada). He is founder, chairman, and CEO of **Clinical Partners, Inc.**, which provides therapy-specific management of HIV and AIDS patients for employers and managed healthcare organizations in California and Texas.

Shaman Pharmaceuticals (South San Francisco, CA) has announced that **Stephanie C. Diaz** has joined the company as vice president and CFO. Previously, she held the position of director of finance at **Hyseq**.

Atlantic Pharmaceuticals (Raleigh, NC) has announced the election of **Robert A. Fildes** as chairman of the board of directors. Dr. Fildes was appointed to the board in October 1997, having previously served as chairman and CEO of **Scotgen Biopharmaceuticals**, president and CEO of **Cetus**, and president of **Biogen**.

Invitrogen (Carlsbad, CA) has named **James R. Glynn** to the position of senior vice president/CFO and member of the board of directors, and **Lewis J. Shuster** to the board of directors. Mr. Glynn comes to **Invitrogen** from **Matrix Pharmaceutical**, where he served as COO, CFO, and as a member of the board. Mr. Shuster is executive vice president, corporate development and CFO of **Pharmacopeia**.

Steven D. Goldby has been named chairman and CEO of **Symyx Technologies** (Santa Clara, CA), replacing **Alejandro Zaffaroni**, who will continue as a member of the board. Mr. Goldby was most recently at **MDL Information Systems**, where he has served as CEO since 1987. He will remain a nonexecutive chairman at **MDL**.

Andaris (Nottingham, UK) has announced that lead founder **David Heath** is retiring as chairman to become a nonexecutive director and consultant to the company. In addition, **Stuart Collinson** has been appointed as CEO, and **Gordon Hall** has been named nonexecutive chairman. Dr. Collinson joins **Andaris** from **Glaxo Wellcome**, where he was most recently therapy area director for the company's hospital and critical care business. Mr. Hall was previously managing director of **Shield Diagnostics**.

Erik Hornnaess has been elected to the board of supervisory directors of **Qiagen NV** (Venlo, Netherlands). Mr. Hornnaess is the former area vice president of **Abbott Laboratories'** diagnostics division in

Europe, Middle East, and Africa, and currently serves as chairman of the board for **Axis Biochemicals**, Norway, and as nonexecutive director of **Radiometer A/S**, Denmark, **Shields Diagnostics**, Scotland, **Orsys/Ilex**, Israel, and **Alpharma and APL Inc.** in the US.

Genentech (South San Francisco, CA) has announced the promotion of **Sean A. Johnston** to vice president, intellectual property. Mr. Johnston joined **Genentech** in October 1990 as patent counsel, and is currently associate general counsel and manager of patent litigation.

Douglas C. Lane has been appointed president and CEO of **Strata Biosciences** (Alameda, CA). He was most recently vice president of genomic research at the prostate cancer foundation **capCURE**, and prior to that was vice president of corporate development for **Hyseq**.

Genzyme Transgenics (Framingham, MA) has appointed **Sandra Nusinoff Lehrman** president and CEO, succeeding **James Geraghty**. Mr. Geraghty will remain chairman of **Genzyme Transgenics**, and will become president of **Genzyme Therapeutics Europe**. Ms. Lehrman most recently held the position of president and COO at **Cytotherapeutics**.

J. Joseph Marr has been appointed president and CEO of **ImmuLogic** (Waltham, MA). Dr. Marr joined **ImmuLogic** as executive vice president for research in July 1996, and was most recently president and COO.

Microscience Ltd. (London) has named **Rod Richards** its new CEO. Most recently, Mr. Richards managed part of **Glaxo Wellcome's** global business development division.

Lidak Pharmaceuticals (San Diego, CA) has named **George Rutland** chairman. Mr. Rutland is also the chairman, CEO, and a director of **Tiapan Corp.**, a management consulting and investment company. He replaces **William Jenkins**, who has served as chairman since January, but is now an outgoing director following a recent board election.

Megabios (Burlingame, CA) has announced the appointment of **Bennet Weintraub** as chief financial officer and vice president of finance. Previously, Mr. Weintraub was CFO and vice president of finance and administration at **Technology Modeling Associates**.



Michael M. Wick has been named president and COO of **Telik** (South San Francisco, CA), and has been elected to the company's board of directors. Dr. Wick joined the company last December as executive vice president, R&D, and COO.

Former US Secretary of Agriculture **Clayton K. Yeutter** has been elected to the board of directors of **Mycogen** (San Diego, CA) to serve until the next annual meeting. He replaces **Roy M. Barbee**, who resigned from the board. Mr. Yeutter served as Secretary of Agriculture under President **George Bush** from February 1989 to February 1991, and as Counselor to the President for Domestic Policy in 1992.

Visit the nature journals on
the world wide web at
<http://www.nature.com>

or access each sister
journal directly:

nature
biotechnology

<http://www.biotech.nature.com>

nature
genetics

<http://www.genetics.nature.com>

nature
medicine

<http://www.medicine.nature.com>

nature
structural
biology

<http://www.structbio.nature.com>